BRIEF—US approval for TheracosBio's SGLT inhibitor

TheracosBio has secured US Food and Drug Administration approval for its SGLT2 blocker Brenzavvy (bexagliflozin).

The product has been developed as a treatment for type 2 diabetes in adults, as an adjunct to diet and exercise.

The company will compete with existing well-established products in this class, including Jardiance (empagliflozin), Farxiga (dapagliflozin), Inovokana (canagliflozin) and Suglat (ipragliflozin).

The market for such products is expected to grow at an average annual rate of over 10% in the years up to 2027.

Commenting on the nod, chief executive Albert Collinson said: “Today's FDA approval represents a significant milestone for TheracosBio and provides an important treatment option to patients who suffer from type 2 diabetes.”